Webinar: Designing Next-Gen Oncology Trials


Over the last 5 years, the FDA has sparked a revolution in the way cancer drugs are being developed. But it’s just getting started. Not only are regulators looking to make additional fundamental changes to the way cancer drugs go through early and late-stage development, groups like the Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy are advocating for new rules that would speed along the next wave of therapies, with a new structure for targeting cancer and handling manufacturing requirements, for example.

We’ll take an in- depth look at this rapidly changing field, with perspectives from the top players influencing this trend. Moderated by Endpoints News editor and founder John Carroll.
Presented by
DIETMAR BERGER
SVP, Global Head of Development
Sanofi


ISRAEL LOWY
SVP Clinical Sciences, Head of Oncology
Regeneron


RAMY IBRAHIM
CMO and VP, Clinical Development
Parker Institute for Cancer Immunotherapy


Watch Now!